Mass spectrometry services such as molecular weight determination, peptide mapping, impurity characterization, and identification of modifications are critical to the characterization of protein therapeutics. As biologics become more complex, extensive structural characterization and analysis is required. To meet the challenge of partnering with clients to bring new, innovative compounds to market faster, Charles River has acquired the Thermo Scientific™ Orbitrap Fusion™ Lumos™, a state-of-the-art mass spectrometer.
The Orbitrap Fusion™ Lumos™ represents a new class of tribrid™ mass spectrometer featuring a unique design supporting a wide diversity of biopharmaceutical mass spectrometry applications. The cutting-edge tribrid™ architecture combines a quadrupole mass filter, with a high-resolution Orbitrap mass analyzer, and a linear ion trap. The instrument’s unique configuration also incorporates three distinct fragmentation modes that may be used either independently or simultaneously: collision-induced dissociation (CID), higher-energy collisional dissociation (HCD), and electron-transfer dissociation (ETD). Two separate ion detection systems for in-depth and high-specificity mass spectrometry characterization projects are available as well. The novel ETD source is strategically located behind the ion funnel for efficient and unbiased fragmentation to quantitatively preserve the connectivity of multiple protein modifications. ETD can be used in combination with the trapping features when multiplexing analytes; and for multi-stage fragmentation (MSn) experiments employing ETD, HCD, and CID to characterize complex disulfide bonding patterns, branched structures including glycans, and to discriminate between isobaric leucine/isoleucine residues.
The combination of these diverse features provides an unprecedented level of ion manipulation and flexibility facilitating advanced characterization of synthetic peptides, complex protein samples, and N- and O-linked glycoproteins. The instrument also provides significant sensitivity enhancements necessary for host cell protein (HCP) quantification and, as such, it is increasingly becoming known as a well-established platform for quantitative interrogation of HCPs, orthogonally supporting traditional ELISA-based approaches. For more information about the Orbitrap Fusion™ Lumos™ or to inquire about service needs that you have contact us at [email protected].